Beactica Therapeutics

Executive Summary

Beactica Therapeutics is a Swedish precision medicine company established in 2012 and headquartered in Uppsala. The company specializes in developing novel small molecule therapeutics, with a core focus on targeted protein degradation (TPD) to address traditionally 'undruggable' targets in oncology and other life-threatening diseases with high unmet medical need. By leveraging TPD, Beactica aims to expand the druggable proteome and provide new treatment options for patients. The company operates in the private sector and has not disclosed funding rounds or valuation, indicating an early-stage status. Its strategic emphasis on precision medicine and TPD aligns with emerging trends in drug discovery, though the lack of publicly disclosed pipeline or clinical candidates adds uncertainty.

Upcoming Catalysts (preview)

• Q4 2026Advancement of lead TPD program into IND-enabling studies40% success
• 2026Series A funding round closing50% success
• H2 2026Presentation of preclinical proof-of-concept data at a major oncology conference60% success